XML 29 R14.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Development Liability | 12 Months Ended
--- | ---
Dec. 31, 2023
Research and Development [Abstract] |
Development Liability | 6. Development Liability On February 28, 2019, the Company entered into a development funding agreement with SFJ (the “SFJ agreement”), under which SFJ agreed to provide funding to the Company to support the development of pegcetacoplan for the treatment of patients with PNH. Pursuant to the agreement, SFJ paid the Company $60.0 million following the signing of the agreement and agreed to pay the Company up to an additional $60.0 million in the aggregate in three equal installments upon the achievement of specified development milestones with respect to the Company’s Phase 3 program for pegcetacoplan in PNH and subject to the Company having cash resources at the time sufficient to fund at least 10 months of the Company’s operations. In June 2019 we amended the SFJ agreement to include an additional $20 million funding payment. SFJ paid us $80.0 million under the amended SFJ agreement between June 2019 and January 2020. Under the SFJ agreement, following regulatory approval by the FDA in May 2021 for the use of systemic pegcetacoplan as a treatment for PNH, the Company became obligated to pay SFJ an initial payment of $4.0 million and then an additional $226.0 million in the aggregate in six additional annual payments with the majority of the payments being made from the third anniversary to the sixth anniversary of regulatory approval. The Company paid SFJ the initial payment of $4.0 million in June 2021, its first annual payment of $11.5 million in May 2022 and its second annual payment of $24.5 million in May 2023. The subsequent annual payments remaining are due and payable in May of each year from 2024 through 2027. Following regulatory approval of systemic pegcetacoplan by the European Medicines Agency(“EMA”) in December 2021, the Company became obligated to pay SFJ an initial payment of $5.0 million and then an additional $225.0 million in the aggregate in six additional annual payments with the majority of the payments being made from the third anniversary to the sixth anniversary of regulatory approval. The Company paid SFJ the initial payment of $5.0 million in January 2022 its first annual payment of $18.0 million in December 2022 and its second annual payment of $31.0 million in December 2023. The subsequent annual payments are due and payable in December of each year from 2024 through 2027. The Company has paid SFJ a total of $94.0 million as of December 31, 2023. Additionally, the Company granted a security interest to SFJ in all of its assets, excluding intellectual property and license agreements to which it is a party. In connection with the grant of the security interest, the Company agreed to certain affirmative and negative covenants, including restrictions on its ability to pay dividends, incur additional debt or enter into licensing transactions with respect to its intellectual property, other than specified types of licenses. From December 15, 2021 to the final annual payment due in December 2027, the development liability will be accreted from its initial carrying amount to the total payment amount using the effective interest rate method under the ASC Topic 835, Interest, over the remaining life of the SFJ agreement. The difference between the carrying amount and the total payment amount is presented as a discount to the development liability. The accretion is recorded as interest expense in the unaudited condensed consolidated statement of operations. The following t able summarizes the development liability (in thousands):
|  | December 31, |  |  |  |
|  | 2023 |  |  | 2022 |  |  | Effective Interest Rate |
Development liability | $ | 366,000 |  |  | $ | 421,500 |  |  |  | 7.91 | %
Less: Unamortized discount to development liability |  | (50,353 | ) |  |  | (76,349 | ) |  |  |
Less: Current portion of development liability, net of discount |  |  | (75,830 | ) |  |  | (29,504 | ) |  |  |
Total long term development liability |  | 239,817 |  |  |  | 315,647 |  |  |  |
As of December 31, 2023 and December 31, 2022 interest expense of $26.0 million and $26.9 million was recorded for the accretion of the development liability. For the period from December 15, 2021 through December 31, 2021, $1.2 million of interest expense was recorded for the accretion of the development liability. Future minimum SFJ payments as of December 31, 2023 is as follows (in thousands):
2024 |  |  | $ |  | 98,750 |
2025 |  |  |  |  | 103,000 |
2026 |  |  |  |  | 109,000 |
2027 |  |  |  |  | 55,250 |
Total future minimum payments |  |  |  |  | 366,000 |

X
- Definition Development liability disclosure. + References No definition available. + Details
Name: | apls_DevelopmentLiabilityDisclosureTextBlock
Namespace Prefix: | apls_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration